Another early event during tumour progression is the mutation of the proto‐oncogene KRAS. KRAS is mutated in 40–50% of human CRCs, with > 75% of these mutations located in codon 12, which lock KRAS in the active GTP‐bound state 6. Here, KRAS is linked to neoplasm.